Michael H. Davidson
#154,380
Most Influential Person Now
Michael H. Davidson's AcademicInfluence.com Rankings
Michael H. Davidsonbiology Degrees
Biology
#11790
World Rank
#15214
Historical Rank
Genetics
#1286
World Rank
#1388
Historical Rank
Molecular Biology
#1855
World Rank
#1884
Historical Rank
Download Badge
Biology
Michael H. Davidson's Degrees
- PhD Genetics Stanford University
Why Is Michael H. Davidson Influential?
(Suggest an Edit or Addition)Michael H. Davidson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Biological Insights From 108 Schizophrenia-Associated Genetic Loci (2014) (6445)
- Dopamine in schizophrenia: a review and reconceptualization. (1991) (1967)
- A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (2016) (1125)
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial (2008) (1040)
- Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects (2016) (736)
- Advancing paternal age and autism. (2006) (629)
- Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. (1999) (594)
- Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. (2017) (567)
- Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes (2017) (517)
- A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. (1994) (426)
- Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. (2004) (386)
- Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. (2005) (350)
- A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. (2002) (349)
- Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. (1998) (340)
- Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. (1995) (293)
- Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). (2009) (282)
- Characteristics of very poor outcome schizophrenia. (1987) (217)
- Strong synaptic transmission impact by copy number variations in schizophrenia (2010) (213)
- Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode (2003) (189)
- Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. (2012) (186)
- Plasma homovanillic acid concentration and the severity of schizophrenic illness. (1985) (182)
- Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. (2013) (178)
- Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. (2005) (174)
- Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. (1998) (172)
- Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study (2004) (172)
- Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. (2005) (168)
- Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. (2005) (164)
- Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. (1993) (158)
- Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. (1997) (154)
- Paternal age and intelligence: implications for age-related genomic changes in male germ cells (2005) (154)
- A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. (1988) (154)
- What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? (2008) (152)
- Homovanillic acid measurement in clinical research: a review of methodology. (1992) (146)
- Treatment of schizophrenia 1999 (1999) (136)
- Affective and impulsive personality disorder traits in the relatives of patients with borderline personality disorder. (1991) (134)
- Risk of cardiovascular disease and sudden death in schizophrenia. (2002) (133)
- Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. (1997) (132)
- Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study (1996) (124)
- Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: Negative symptoms (1992) (121)
- Postmortem studies in schizophrenia. (1998) (114)
- Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study (2009) (113)
- Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. (1996) (109)
- Premorbid Intellectual Functioning and Risk of Schizophrenia and Spectrum Disorders (2006) (108)
- Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST) (2009) (107)
- Severe cognitive impairment in elderly schizophrenic patients: A clinicopathological study (1993) (100)
- Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures. (1986) (96)
- Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. (1997) (96)
- Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis. (2002) (93)
- Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. (1988) (93)
- Complement genes contribute sex-biased vulnerability in diverse illnesses (2020) (92)
- ELABORATION ON IMMIGRATION AND RISK FOR SCHIZOPHRENIA (2007) (91)
- A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. (2012) (91)
- Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-L. (2005) (91)
- A long‐term, multicenter, open‐label study of risperidone in elderly patients with psychosis (2000) (90)
- The Longitudinal Stability of Cognitive Impairment in Schizophrenia (1995) (88)
- Continuous performance tests in schizophrenic patients: Stimulus and medication effects on performance (1991) (88)
- Induction of depression with oxotremorine in patients with Alzheimer's disease. (1987) (88)
- RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects (1987) (84)
- Eye tracking impairment in clinically identified patients with schizotypal personality disorder. (1990) (84)
- A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization (2006) (82)
- CSF homovanillic acid in schizotypal personality disorder. (1993) (82)
- AMPA Receptor Binding and Subunit mRNA Expression in Prefrontal Cortex and Striatum of Elderly Schizophrenics (1998) (80)
- Advanced parental age at birth is associated with poorer social functioning in adolescent males: shedding light on a core symptom of schizophrenia and autism. (2008) (79)
- Discontinuity in the genetic and environmental causes of the intellectual disability spectrum (2015) (77)
- Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. (1991) (77)
- Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. (2002) (76)
- Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex (1996) (75)
- Premorbid sociosexual functioning and long-term outcome in schizophrenia. (1989) (74)
- Social and cognitive functioning, urbanicity and risk for schizophrenia (2007) (71)
- Cortical cholinergic markers in schizophrenia (1994) (69)
- 4-Aminopyridine in the treatment of alzheimer's disease (1988) (66)
- Serotonin function and treatment response to clozapine in schizophrenic patients. (1993) (66)
- Premorbid functioning and treatment response in recent-onset schizophrenia (2006) (66)
- Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function (1994) (64)
- The relationship between risk of hospitalization for schizophrenia, SES, and cognitive functioning. (2011) (63)
- Schizophrenia and violent crime: a population-based study (2014) (62)
- Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. (1996) (62)
- The Puzzle of Processing Speed, Memory, and Executive Function Impairments in Schizophrenia: Fitting the Pieces Together (2015) (61)
- Cognitive impairment as a target for pharmacological treatment in schizophrenia (1995) (61)
- Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypes. (2005) (61)
- Control of exogenous factors affecting plasma homovanillic acid concentration (1987) (60)
- L-dopa challenge and relapse in schizophrenia. (1987) (59)
- Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. (1991) (57)
- Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. (2017) (57)
- Gender differences in premorbid cognitive performance in a national cohort of schizophrenic patients (2000) (56)
- Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. (1993) (55)
- Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia (1993) (55)
- Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophrenia (2003) (54)
- Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders. (1993) (53)
- The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients (1997) (53)
- The cost of cognitive impairment in schizophrenia (1995) (53)
- Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: A population-based study (2006) (53)
- Assessment of the central dopaminergic index of plasma HVA in schizophrenia. (1995) (52)
- Assessment of dementia in elderly schizophrenics with structured rating scales (1992) (52)
- Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. (1987) (51)
- Inositol levels are decreased in postmortem brain of schizophrenic patients (1998) (49)
- Serotonin function in schizophrenia: Effects of meta- chlorophenylpiperazine in schizophrenia patients and healthy subjects (1992) (49)
- Event-related potentials in schizotypal personality disorder. (1996) (49)
- Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms (1991) (47)
- Cognitive performance of male adolescents is lower than controls across psychiatric disorders: a population‐based study (2004) (46)
- Suicide risk assessment among psychiatric inpatients: a systematic review and meta-analysis of high-risk categories (2017) (45)
- Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment (1995) (44)
- CHARACTERISTICS OF ELDERLY PSYCHIATRIC PATIENTS RETAINED IN A STATE HOSPITAL DURING DOWNSIZING: A PROSPECTIVE STUDY WITH REPLICATION (1997) (43)
- Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration. (1987) (42)
- CSF Somatostatin in alzheimer's disease, depressed patients, and control subjects (1988) (41)
- Symptom stability in geriatric chronic schizophrenic inpatients: A one-year follow-up study (1996) (40)
- A Nation-Wide Study on the Percentage of Schizophrenia and Bipolar Disorder Patients Who Earn Minimum Wage or Above. (2016) (40)
- Efficacy and safety of long‐acting risperidone in elderly patients with schizophrenia and schizoaffective disorder (2004) (40)
- Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? (2000) (39)
- Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. (1990) (39)
- Body mass index and future schizophrenia in Israeli male adolescents. (2004) (39)
- Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia (2015) (39)
- Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale (1996) (38)
- Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures. (1986) (38)
- Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. (1993) (37)
- Prostaglandin receptor sensitivity in psychiatric disorders. (1986) (37)
- Attentional predictors of clinical change during neuroleptic treatment in schizophrenia (1993) (36)
- Do psychiatric registries include all persons with schizophrenia in the general population? A population-based longitudinal study (2012) (35)
- Predictors of Response to Neuroleptic Treatment in Schizophrenia (1993) (35)
- Familial schizophrenia and treatment response. (1987) (34)
- Effects of the D-1 agonist SKF-38393, combined with haloperidol, in schizophrenic patients: A preliminary report (1989) (34)
- Agitation and postdexamethasone cortisol levels in Alzheimer's disease. (1992) (34)
- The Association between Negative Symptoms, Psychotic Experiences and Later Schizophrenia: A Population-Based Longitudinal Study (2015) (34)
- Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. (1997) (33)
- Lateral ventricular enlargement in schizotypal personality disorder (1995) (33)
- Memory impairment in schizophrenic patients with tardive dyskinesia (1988) (32)
- Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. (2012) (32)
- Performance of chronic schizophrenic patients on cognitive neuropsychological measures sensitive to dementia (1996) (31)
- Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice? (2003) (31)
- Longitudinal association between epilepsy and schizophrenia:A population-based study (2014) (31)
- Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients (1991) (30)
- Kraepelinian schizophrenia: a subgroup of schizophrenia? (1988) (30)
- The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial (2019) (30)
- Risperidone in Elderly Schizophrenic Patients: An Open-Label Trial. (1996) (29)
- Early response to clozapine in schizophrenia. (1994) (29)
- Cognitive impairment in geriatric chronic schizophrenic patients: a cross‐national study in New York and London (1997) (28)
- Limitations of controlled augmentation trials in schizophrenia (1997) (27)
- Leukotomy and aging in chronic schizophrenia: a followup study 40 years after psychosurgery. (1993) (27)
- Symptom severity and cognitive impairment in chronically hospitalised geriatric patients with affective disorders (1997) (27)
- Plasma homovanillic acid in schizotypal personality disorder. (1991) (27)
- Religiosity as a protective factor against suicidal behaviour (2016) (27)
- In-patient suicide: selection of people at risk, failure of protection and the possibility of causation (2017) (26)
- Comparative treatments of depression (2002) (26)
- Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial. (2020) (26)
- Measurement of plasma homovanillic acid concentrations in schizophrenic patients (1990) (24)
- Cognitive impairment and psychosis in schizophrenia: independent or linked conditions? (2019) (24)
- Comments on risk for schizophrenia (2005) (24)
- Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. (2018) (24)
- Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. (2019) (23)
- Impaired Reading Comprehension and Mathematical Abilities in Male Adolescents With Average or Above General Intellectual Abilities Are Associated With Comorbid and Future Psychopathology (2007) (23)
- Dedifferentiation and substitute strategy: Deconstructing the processing-speed impairment in schizophrenia (2012) (23)
- Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). (2023) (23)
- Early diagnosis of schizophrenia — the first step towards secondary prevention (2000) (23)
- Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: Symptom structure in geriatric and nongeriatric samples (1994) (22)
- Cholinergic strategies in the treatment of Alzheimer's disease (1991) (21)
- Developmental Trajectories of Impaired Community Functioning in Schizophrenia. (2016) (20)
- Time course and clinical predictors of treatment response in schizophrenia (1991) (20)
- The longitudinal stability of cognitive impairment in schizophrenia: Mini mental scores at one and two year follow-ups in geriatric inpatients (1994) (20)
- Verbal fluency deficits in geriatric and nongeriatric chronic schizophrenic patients. (1997) (19)
- Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs (2007) (19)
- Lecithin and piracetam in Alzheimer's disease (1987) (19)
- Cognitive impairment as a diagnostic criterion and treatment target in schizophrenia (2019) (19)
- Platelet alpha2-adrenergic receptor function in psychiatric disorders (1988) (18)
- Serotonin, dopamine and their interactions in schizophrenia (1993) (18)
- Subtle Cognitive Dysfunction in Nonaffected Siblings of Individuals Affected by Nonpsychotic Disorders (2008) (18)
- Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. (1995) (17)
- Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine (1994) (17)
- CNS infection in childhood does not confer risk for later schizophrenia: A case–control study (2010) (17)
- Understanding the association between advanced paternal age and schizophrenia and bipolar disorder (2019) (17)
- IQ and obesity in adolescence: a population‐based, cross‐sectional study (2014) (17)
- Psychobiology of personality disorders: pharmacologic implications. (1987) (17)
- Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression (2020) (17)
- Apolipoprotein E4 in schizophrenia: A study of one hundred sixteen cases with concomitant neuropathological examination (1997) (17)
- Pisa syndrome in Alzheimer's disease (1988) (16)
- Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. (1987) (16)
- Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients (1985) (16)
- Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. (1995) (16)
- The brief negative symptom scale (BNSS): Sensitivity to treatment effects (2017) (16)
- Demographic, Behavioral, and Psychiatric Risk Factors for Suicide. (2016) (15)
- Refractive errors and schizophrenia (2009) (14)
- in Patients With Alzheimer's Disease (1987) (14)
- Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects (1992) (14)
- Eff ectiveness of antipsychotic drugs in fi rst-episode schizophrenia and schizophreniform disorder : an open randomised clinical trial (2008) (13)
- Haloperidol and clozapine treatment and their effect onM-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine (2005) (13)
- Cyclic-AMP production by polymorphonuclear leukocytes in psychiatric disorders (1989) (13)
- Schizophrenia and the Cochrane Collaboration (1994) (12)
- Genetic and environmental influences on the overlap between premorbid IQ, premorbid social adjustment and schizophrenia: A population-based twin and sibling study (2008) (12)
- A pilot study of clonidine plus physostigmine in Alzheimer's disease. (1994) (12)
- Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. (1989) (12)
- A population-based longitudinal study of suicide risk in male schizophrenia patients: Proximity to hospital discharge and the moderating effect of premorbid IQ (2015) (11)
- Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia (2005) (11)
- Effect of concurrent distraction on communication failures in schizophrenic patients II. Medication status correlations (1991) (10)
- Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort (2020) (10)
- Treatment-refractory schizophrenia (2004) (10)
- The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia (2018) (10)
- Endocrine changes in Alzheimer's disease. (1988) (10)
- Self‐report of family functioning and risk for psychotic disorders in male adolescents with behavioural disturbances (2008) (9)
- Effects of ipsapirone in healthy subjects: a dose-response study (1994) (9)
- Effect of m-Chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects (1992) (9)
- Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. (2021) (9)
- Has deinstitutionalization affected inpatient suicide? Psychiatric inpatient suicide rates between 1990 and 2013 in Israel (2016) (9)
- Serotonin receptor responsivity in schizophrenia (1993) (8)
- Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs. (2021) (8)
- Plasma Homovanillic Acid and Performance on Motor and Cognitive Tasks in Community-Dwelling Elderly: MacArthur Studies of Successful Aging (1994) (8)
- Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation (1992) (8)
- Increased number of offspring in first degree relatives of psychotic individuals: a partial explanation for the persistence of psychotic illnesses (2009) (8)
- Frontal functioning and plasma HVA in the relatives of schizophrenic patients (1992) (8)
- On the Value of Measuring Dopamine, Norepinephrine and Their Metabolites in Schizophrenia (1993) (7)
- Dementia in elderly schizophrenic patients (1991) (7)
- Growth hormone response to edrophonium in patients with Alzheimer's disease and normal control subjects. (1988) (7)
- Dysthymia in male adolescents is associated with increased risk of later hospitalization for psychotic disorders: a historical‐prospective cohort study (2008) (7)
- Dopaminergic dysregulation in schizophrenia: A target for new drugs (1986) (7)
- Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: A historical-prospective cohor study (2003) (6)
- Can premorbid and prodromal markers associated with psychosis be utilized for early detection and secondary prevention of schizophrenia? (2001) (6)
- The association between premorbid cognitive ability and social functioning and suicide among young men: A historical-prospective cohort study (2017) (6)
- A Population-Based Longitudinal Study of Symptoms and Signs Before the Onset of Psychosis. (2017) (6)
- Physostigmine in patients with Alzheimer's disease. (1986) (6)
- Control of Renal Factors in Plasma Homovanillic Acid Measurements (1998) (6)
- Endocrine changes in Alzheimer's disease. (1988) (6)
- The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial (2021) (6)
- Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study (2012) (6)
- Long-term safety of risperidone. (2001) (6)
- 47 SCHIZOPHRENIA : COURSE OVER THE LIFETIME (2002) (5)
- Platelet phospholipid synthesis in Alzheimer's disease (1991) (5)
- Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients. (1987) (5)
- Effect of apomorphine infusion on plasma homovanillic acid in normal subjects. (1986) (5)
- Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements (2020) (5)
- Dementia in elderly schizophrenic patients: reviewing the reviews (1997) (5)
- Attentional and clinical neuroleptic response in schizophrenia: a study with the continuous performance test. (1997) (5)
- Symptom severity and cognitive impairment in elderly schizophrenic patients (1993) (4)
- Cognitive decline in geriatric chronic schizophrenic patients: evidence for a neurodegenerative process? (1996) (4)
- Schizotypal traits and neuropsychological performance: The role of processing speed (2020) (4)
- Age disorientation in chronically hospitalized patients with mood disorders (1996) (4)
- Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects (1992) (4)
- POSITIVE SYMPTOMS RESPOND TO ADD-ON ASPIRIN IN SCHIZOPHRENIA PATIENTS WITH HIGH SERA CRP LEVELS: A POST-HOC ANALYSIS OF AN RCT (2014) (4)
- Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis (1994) (4)
- Long-term efficacy, safety, and tolerability of risperidone in elderly psychotic patients (1999) (4)
- Prodromal Schizophrenia: The Dilemma of Prediction and Early Intervention (2004) (3)
- Abnormal functional correlate precedes loss of structural asymmetry in the paracingulate sulcus in adolescent psychosis (2006) (3)
- Somatostatin and NPY deficits in schizophrenic cortex (1995) (3)
- Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms (1990) (3)
- Neuropathologic study of 101 elderly institutionalized schizophrenics (1995) (3)
- Is non-pharmacological treatment an option for certain schizophrenia patients? (2014) (3)
- Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions (2005) (3)
- Methodological issues in PET scan evaluation of dopamine supersensitivity in tardive dyskinesia (1989) (3)
- Risk of hospitalization for psychiatric disorders among siblings and parents of probands with psychotic or affective disorders: A population-based study (2017) (3)
- Familial risk of schizophrenia and ventricular size on CT (1994) (3)
- Alzheimer's disease: Tacrine and tacrine metabolite concentrations in plasma and cognitive change (1995) (3)
- Who has poor insight, my patient suffering from schizophrenia or myself? (2023) (3)
- Human and Animal Studies With Cholinergic Agents: How Clinically Exploitable is the Cholinergic Deficiency in Alzheimer’s Disease (1986) (3)
- Are all antipsychotics equal? – Authors' reply (2008) (3)
- Acute administration of alprazolam has no effect on plasma homovanillic acid concentration in normal subjects (1991) (3)
- Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). (2023) (3)
- Lack of effect of laboratory-provoked anxiety on plasma homovanillic acid concentration in normal subjects (1996) (3)
- Misreporting of Results of Research in Psychiatry. (2021) (2)
- Acute administration of alprazolam has no effect on plasma homovanillic acid concentration in normal subjects (1989) (2)
- Plasma homovanillic acid concentrations decrease in responders, but not in non-responders, to neuroleptic treatment (1991) (2)
- RESULTS OF PHASE 2B EAGLE TRIAL; A DOUBLE BLIND PLACEBO CONTROL STUDY EVALUATING THE EFFICACY AND SAFETY OF BL-1020, A GABA ENHANCED ANTIPSYCHOTIC FOR THE TREATMENT OF SCHIZOPHRENIA (2010) (2)
- Schizophrenia, Metabolic Disorders, and Cardiovascular Disease (2004) (2)
- DEMENTIA‐LIKE SYMPTOMS IN ELDERLY SCHIZOPHRENIC PATIENTS (1992) (2)
- Neuropsychological correlates of central monoamine function in chronic schizophrenia (1993) (2)
- Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia (2022) (2)
- Serotonin receptor sensitivity in schizophrenia (1991) (1)
- Time course and clinical predictors of neuroleptic response in schizophrenia (1989) (1)
- Cognitive impairment and clinical symptoms in geriatric schizophrenic inpatients and outpatients (1994) (1)
- Commentary to “Late-onset Schizophrenia and Late Paraphrenia” (1995) (1)
- Spect imaging of cognitive decline in elderly schizophrenia (1995) (1)
- Characterization of the relationship between negative symptoms and cognitive impairment in schizophrenia (1995) (1)
- Evidence for altered cerebral laterality in early onset schizophrenia (2004) (1)
- 6-1 Psychosis in the elderly (1997) (1)
- ALZHEIMERʼS DISEASE AND RELATED NEURODEGENERATIVE DISEASES IN ELDERLY SCHIZOPHRENIC PATIENTS: A POST-MORTEM NEUROPATHOLOGIC STUDY OF 100 CASES. DP Purohit (1995) (1)
- Increased risk for schizophrenia in siblings of patients with schizotypal personality disorder (2003) (1)
- THE MULTIDIMENSIONAL STRUCTURE OF PROCESSING SPEED IN HEALTHY INDIVIDUALS AND SCHIZOPHRENIA PATIENTS (2010) (1)
- Reflections on the inclusion of cognitive impairment in the diagnostic criteria for schizophrenia (2008) (1)
- Neuropsychological correlates of central monoamine function in schizophrenia (1993) (1)
- Proceedings on Serotonin, dopamine and their interactions in schizophrenia (1993) (1)
- Vulnerability and plasticity of monoamine neurotransmitter systems in affective and personality disorders (1990) (1)
- Should Diagnosis Drive Development of Psychotropic Drugs (2007) (1)
- Sodium Nitroprusside Infusion for the Treatment of Schizophrenia (2020) (1)
- Significant decrease in psychopathology within three days of haloperidol treatment in chronic schizophrenia (1992) (1)
- Age disorientation in chronically institutionalized affective disorder patients: Similarity to schizophrenia (1995) (1)
- [The search for biological markers in schizophrenia]. (1988) (1)
- MEASUREMENTS OF PLASMA HOMOVANILLIC ACID IN SCHIZOPHRENIC PATIENTS (1992) (1)
- FIRST IN CLASS GABA ENHANCED ANTIPSYCHOTIC FOR SCHIZOPHRENIA: RESULTS OF PHASE IIA IN SCHIZOPHRENIC PATIENTS (2008) (1)
- Naturalistic study of antipsychotic medications prescribed to elderly patients with schizophrenia (1998) (1)
- Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo? (2020) (1)
- 229 Ionotropic glutamate receptor mRNA expression in schizophrenia (1997) (1)
- Risk factors for schizophrenia in adolescents (2004) (1)
- Prevalence and correlates of stable negative symptom subtypes in geriatric chronic schizophrenic inpatients (1994) (1)
- D-SERINE VS. PLACEBO IN THE TREATMENT OF NEGATIVE SYMPTOMS AND COGNITIVE IMPAIRMENT OF SCHIZOPHRENIA (2008) (1)
- Kraepelinian schizophrenia: A replication in an independent sample (1991) (1)
- PREMORBID IQ AND SOCIAL FUNCTIONING DEFICITS AND SCHIZOPHRENIA RISK: EVIDENCE FOR SHARED GENETIC INFLUENCES ON NEURODEVELOPMENT (2011) (1)
- 288 Cognitive decline in geriatric schizophrenic inpatients (1997) (1)
- Correlations between temporal lobe synaptic protein immunoactivity and schizophrenic psychosis (1995) (1)
- Male adolescents with affective disorders are at increased risk of later hospitalization for schizophrenia: A historical-prospective cohort study (2003) (0)
- S.29.01 Which factors determine publication rates of clinical trials and how can these rates be improved? (2016) (0)
- Dopaminergic correlates of attentional performance in unmedicated schizophrenic patients (1992) (0)
- Reply (2010) (0)
- Visuo-manual testing in the diagnosis of extra-pyramidal side effects of anti-psychotic drugs (1998) (0)
- DO SOCIAL AND COGNITIVE DYSFUNCTIONS MEDIATE THE ASSOCIATION BETWEEN ADVANCE PATERNAL AGE AND SCHIZOPHRENIA? (2010) (0)
- Memory functions in chronic schizophrenic patients: Age related changes (1995) (0)
- 109. Rates of Nonpublication of Trials Funded by the Stanley Medical Research Institute (2017) (0)
- Dementia in elderly schizophrenics (1992) (0)
- 15:45 VIOLENT CRIMES IN PEOPLE WITH SCHIZOPHRENIA (2012) (0)
- Dopamine receptor gene expression in postmortem human brain: An in situ hybridization study (1995) (0)
- S05.06 The neuropathology of schizophrenia dementia (2000) (0)
- Diagnostic yield of brain CT in a limited-access environment. (1998) (0)
- Change in subtype presentation in schizophrenics. (1989) (0)
- Effect of haloperidol on CSF monoamine metabolites in schizophrenia. Symptomatic improvement is related to altered dopamine-serotonin interaction (1992) (0)
- PREMORBID INTELLECTUAL FUNCTIONING AND SOCIAL ADJUSTMENT AND RISK OF DEVELOPING SCHIZOPHRENIA, PSYCHOTIC OR NON-PSYCHOTIC BIPOLAR DISORDER: A POPULATION LONGITUDINAL STUDY (2008) (0)
- P.3.a.015 Elaboration on the association between urbanicity and schizophrenia (2006) (0)
- P.3.e.011 Psychotic disorders and risk for later cancer: a cohort study (2008) (0)
- NATION-WIDE EMPLOYMENT STATUS IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDERS (2014) (0)
- IS COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA A REALISTIC TARGET FOR PHARMACOLOGICAL INTERVENTION? (2008) (0)
- Identifying an elusive target with the help of an unproven technique (2021) (0)
- Premorbid functioning and treatment response Premorbid functioning and treatment response in recent-onset schizophrenia in recent-onset schizophrenia (2005) (0)
- Poster #S76 A RANDOMIZED TRIAL ADMINISTERING RALOXIFENE VS PLACEBO AS ADD-ON TO ANTIPSYCHOTICS IN POST-MENOPAUSAL FEMALE PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER (2014) (0)
- A comparison of ventricular size in familial versus sporadic schizophrenia (1995) (0)
- Clinical investigations of plasma homovanillic acid concentrations (1990) (0)
- Dopamine receptor gene expression in postmortem brain in schizophrenia (1995) (0)
- 246 APOE4 allele frequency is not increased in demented schizophrenics: A study of 116 patients with concomitant postmortem examination (1997) (0)
- Attentional correlates of clinical change during neuroleptic treatment in schizophrenia (1993) (0)
- Social and Cognitive Functioning as Risk Factors for Suicide : A Historical-Prospective Cohort Study (2013) (0)
- Time course and clinical predictors of neuroleptic response in schizophrenia (1989) (0)
- P.3.b.008 Cognitive deficit in schizophrenia specific or general: neuropsychological study (2014) (0)
- Chronic Schizophrenia, II: Biological Measures (1986) (0)
- VKučinskas-2001-2016 (2016) (0)
- P.3.a.015 Do psychiatric registries include all persons with schizophrenia in the general population? A population-based longitudinal study (2012) (0)
- Postmortem study of DA, 5HT, and their metabolites in cortex of schizophrenics and controls (1995) (0)
- 335 Cognitive correlates of the deficit syndrome in geriatric schizophrenia (1997) (0)
- 355. Efficacy and Safety of MIN-101: A Drug for the Treatment of Negative Symptoms in Schizophrenia (2017) (0)
- Patterns of Clinical Efficacy for Antipsychotic Drugs (1996) (0)
- ORIGINAL ARTICLES i Neuropeptide Deficits in Schizophrenia Alzheimer's Disease Cerebral Cortex (1996) (0)
- Kin advantages in schizophrenia's prevalence. Authors' reply (2010) (0)
- NEURONAL PERIKARYAL CONTRIBUTION TO THE DEVELOPMENT OF THE NEURITIC PLAQUE: EVALUATION THROUGH THE EXAMINATION OF PREFRONTAL CORTEX IN ELDERLY SCHIZOPHRENICS WHO UNDERWENT PREFRONTAL LEUKOTOMY (1993) (0)
- m-chlorophenylpiperazine as a probe of serotonin function in schizophrenia (1992) (0)
- Psychotic disorders and risk for later cancer: a cohort study (2008) (0)
- CNS INFECTIONS DURING CHILDHOOD AND RISK OF SCHIZOPHRENIA: A CASE CONTROL STUDY (2008) (0)
- WHAT IS THE LONG TERM OUTCOME OF SCHIZOPHRENIA? (2014) (0)
- Age at first birth in women is genetically associated with increased risk of schizophrenia (2018) (0)
- Alzheimer's and Parkinson's disease. New drug development, and innovative experimental approaches (1986) (0)
- Methodological issues in the pet scan evaluation of F-18 NMS binding in tardive dyskinesia (TD) (1989) (0)
- Remote Assessment of Negative Symptoms of Schizophrenia (2023) (0)
- Non-psychotic, non-major affective psychiatric disorders in adolescent boys were associated with greater schizophrenia risk (2002) (0)
- Effects of the D-1 agonist SKF-38393, combined with haloperidol, in schizophrenic patients: A preliminary report (1989) (0)
- Optic nerve head in Alzheimer's disease patients (1989) (0)
- P.3.a.024 Elaboration of immigration and risk for non affective psychotic disorders (2007) (0)
- P.8.a.012 Subtle cognitive impairments in siblings of male adolescents with non-psychotic psychiatric disorders (2006) (0)
- Heterogeneity in undifferentiated schizophrenia (1989) (0)
- Neuropeptides discriminate brains of schizophrenics from normals (1994) (0)
- Using clinical data bases to study schizophrenia. (2008) (0)
- 382. Cognitive impairment in elderly schizophrenics: Phenomenology, longitudinal course, and neuropathology (1996) (0)
- Cognitive test scores are lower in adolescent cigarette smokers compared to non-smokers: a population-based study (2008) (0)
- [Use of cannabis in adolescence and risk of schizophrenia]. (2003) (0)
- Longitudinal classification in schizophrenia: The relationship between kraepelinian and deficit syndrome subtypologies (1994) (0)
- MODELING THE EXPRESSION AND COURSE OF DEVELOPMENTAL ABNORMALITIES PRECEDING ADULT SCHIZOPHRENIA: CHARACTERIZATION OF A NEW DEVELOPMENTAL ULTRA-HIGH-RISK GROUP IN 2 BIRTH COHORTS (2011) (0)
- Effects of D1 agonist in schizophrenia (1989) (0)
- Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Is the panss a valid scale? (1994) (0)
- A review of statistical design in controlled treatment trials in schizophrenia (1994) (0)
- Correction for Reichenberg et al., Discontinuity in the genetic and environmental causes of the intellectual disability spectrum (2017) (0)
- Poster #132 THE GROUP OF SCHIZOPHRENIAS: EVIDENCE FOR DIFFERENTIAL DEVELOPMENTAL TRAJECTORIES IN SCHIZOPHRENIA AND BIPOLAR DISORDER (2012) (0)
- Plasma HVA correlates of attentional performance in unmedicated schizophrenics (1991) (0)
- 65-81 Long-term treatment of elderly psychotic patients with risperidone (1997) (0)
- The Impact of Atypical Antipsychotics on Weight Gain (2004) (0)
- S.26.05 Environmental and genetic risk factors in schizophrenia on ‘cognitive and social function as endophenotypes’ (2003) (0)
- EFFECT OF NEUROLEPTIC TREATMENT ON CSF MONOAMINE METABOLITES: RELEVANCE OF 5HT‐DA INTERACTIONS IN SCHIZOPHRENIA. (1992) (0)
- SEROTONIN DYSFUNCTION IN TREATMENT‐REFRACTORY SCHIZOPHRENIA (1992) (0)
- P.3.07 Is it possible to identify future patients in the months before the first psychotic episode? A population-based study (2007) (0)
- Challenges and options in the treatment of schizophrenia (2007) (0)
- 134. AMPA subunit gene expression in the frontal cortices of schizophrenics (1996) (0)
- Differential diagnosis and cognitive impairment in elderly psychiatric inpatients (1993) (0)
- P.3.a.014 Offsprings of parents and siblings of psychotic patients:a possible explanation for the persistence of psychosis (2006) (0)
- Serotonin receptor responsitivity in schizophrenia (1993) (0)
- Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease. (1993) (0)
- Nocturnal growth hormone secretion in Schizophrenic patients and Healthy Subjects Lisa Webster, René S. Kahn, Michael Davidson, Jack Hirschowitz, Clare Moore, Kenneth L. Davis Mount Sinai School of Medicine, Bronx Veterans Administration Hospital, Bronx, NY 10468. (1992) (0)
- Temporal and age disorientation are primary features of cognitive impairment in geriatric schizophrenic inpatients (1994) (0)
- Poster #181 PREDICTORS OF REAL-WORLD OUTCOMES IN SCHIZOPHRENIA PATIENTS, THEIR FAMILY MEMBERS AND CONTROL SUBJECTS (2012) (0)
- Neuroleptic Treatment, Symptoms of Schizophrenia, and Plasma Homovanillic Acid Concentrations Revisited-Reply (1992) (0)
- RISK FOR SUICIDE AMONG INDIVIDUALS WITH SCHIZOPHRENIA (2010) (0)
- Clinical predictors of exacerbation during neuroleptic discontinuation (1989) (0)
- S-30-1 Dopamine receptor transcript expression in schizophrenia (1996) (0)
- Use of ancillary tests in the differential diagnosis of psychotic psychiatric inpatients (1998) (0)
- Epidemiology of Cardiovascular Disease and Major Metabolic Risk Factors (2004) (0)
- 261. Determinants of category and phonemic fluency dificits in chronic schizophrenics (1996) (0)
- CHARACTERISTICS OF POOR OUTCOME SCHIZOPHRENIA (1992) (0)
- 21. Differential patterns of dopamine receptor gene expression in schizophrenia (1996) (0)
- [The electroencephalogram in psychiatric patients]. (1998) (0)
- Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial. (2022) (0)
- Influence of neuroleptics on symptom structure in schizophrenia (1995) (0)
- DO PSYCHIATRIC CASE REGISTERS PROVIDE ACCURATE ESTIMATES OF TRUE RATES OF SCHIZOPHRENIA? (2010) (0)
- 111. Efficacy and Safety of MIN-101: A New Drug for the Treatment of Negative Symptoms in Schizophrenia. A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial (2017) (0)
- 14.1 VIOLENT CRIME IN SCHIZOPHRENIA AND BIPOLAR DISORDER: A POPULATION-BASED STUDY (2018) (0)
- Evidence for an early antipsychotic effect of neuroleptics in patients with chronic schizophrenia (1991) (0)
- [Cholinergic agents in the treatment of Alzheimer's disease]. (1987) (0)
- S.03.05 CNS infections during childhood and risk for schizophrenia: a historical-prospective study on 3,500 children hospitalised for CNS infections in childhood (2009) (0)
- P.3.f.002 CNS infections during childhood and risk for schizophrenia: a case control study (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael H. Davidson?
Michael H. Davidson is affiliated with the following schools:
